00:29 , May 25, 2019 |  BC Extra  |  Financial News

New IPO filings include BridgeBio, Dermavant, Prevail, Atreca, Akero

In a week in which two biotechs went public and a third opted for a billion-dollar takeout instead of an IPO, five companies filed on Friday to list on NASDAQ in IPOs that could raise...
20:49 , May 24, 2019 |  BioCentury  |  Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
21:08 , May 23, 2019 |  BC Innovations  |  Emerging Company Profile

Obsidian: Fine-tuning therapeutic protein expression with approved drugs

Obsidian is building a tool kit of engineered proteins whose expression can be finely tuned with FDA-approved small molecules, and its first application is in boosting the efficacy of cell therapies through a deal with...
20:44 , May 22, 2019 |  BC Extra  |  Company News

May 22 Company Quick Takes: Lilly adds warning to Verzenio's Japanese label; plus Janssen, a pair of China approvals and more

Lung disease warning for Lilly breast cancer drug in Japan  Eli Lilly and Co. (NYSE:LLY) told BioCentury it has updated the Japanese label of breast cancer drug Verzenio abemaciclib to include a warning for interstitial...
20:23 , May 22, 2019 |  BC Extra  |  Company News

In a rare M&A move, Amgen proposes to acquire partner Nuevolution

In what would be its first acquisition since 2015, Amgen offered on Wednesday to buy Copenhagen-based small molecule discovery company Nuevolution for about $167 million in cash. Amgen Inc. (NASDAQ:AMGN) has proposed to pay SEK32.50...
00:17 , May 18, 2019 |  BioCentury  |  Politics, Policy & Law

Cutting through the noise: the handful of pricing proposals the Trump administration or Congress may enact

Scores of proposals for reducing the cost of drugs are swirling around Congress, the White House and the U.S. Department of Health and Human Services, but only a few merit attention outside the beltway. Eliminating...
21:19 , May 17, 2019 |  BioCentury  |  Emerging Company Profile

89bio: standing out in the NASH crowd

89bio thinks it can differentiate itself from companies targeting NASH as an inflammatory and fibrotic disease by attacking it as a metabolic disorder and addressing its root cause with an FGF analog that could be...
21:36 , May 16, 2019 |  BC Extra  |  Clinical News

May 16 ASCO Quick Takes: Aduro ends MM trial; plus Puma, PharmaMar, Genocea, J&J

Abstracts were released late Wednesday ahead of the American Society of Clinical Oncology meeting starting May 31 in Chicago. See below for BioCentury's second round of Quick Takes on selected abstracts (see "May 15 ASCO...
00:06 , May 16, 2019 |  BC Extra  |  Clinical News

May 15 ASCO Quick Takes: After-hours pop for Iovance, MacroGenics; plus Takeda, Amgen, Forty Seven

Abstracts were released late Wednesday ahead of the American Society of Clinical Oncology meeting starting May 31 in Chicago. See below for BioCentury's first round of Quick Takes on selected abstracts. Iovance gains on 44%...
23:54 , May 8, 2019 |  BC Extra  |  Company News

May 8 Company Quick Takes: Takeda selling Shire eye drug to Novartis in $3.4B deal; plus BioNTech, Third Rock’s Thrive and more

Takeda off-loads Xiidra, TachoSil  Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) will sell Xiidra lifitegrast to Novartis AG (NYSE:NVS; SIX:NOVN) for $3.4 billion up front, plus $1.9 billion in milestones. Takeda said divesting the dry eye...